Welcome to the Boehringer Ingelheim Congress Hub Oncology
For Boehringer Ingelheim, Cancer Care is personal - Today and for Future Generations. Our long-term commitment to oncology is to pursue leading science to develop innovative cancer treatments across different tumor types.
Publication @ ASCO 2024
A Phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)
Author(s): Sarkaria et al.
Tumor type(s): GBM
Compound/Target: MDM2-p53
Tumor type(s): GBM
Compound/Target: MDM2-p53
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Tumor type(s): SCLC
Compound/Target: DLL3/TcE
Tumor type(s): SCLC
Compound/Target: DLL3/TcE
Phase I, open-label dose escalation to investigate the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors
Author(s): Tolcher et al.
Tumor type(s): Solid tumors
Tumor type(s): Solid tumors
Publication @ AACR 2024
MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance
Author(s): Hoffmann et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models
Author(s): Peng et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications
Author(s): Tedeschi et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
The ADC payload PNU-159682 is highly active in a wide range of cancer indications by inducing DNA damage and cell death via a distinct mode of action
Author(s): Kaiser et al.
Tumor type(s): Solid tumors
Compound/Target: MRAS
Tumor type(s): Solid tumors
Compound/Target: MRAS
Publication @ ESMO Sarcoma 2024
Brightline-4: A Phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma
Author(s): Schuetze et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Publication @ ENETS 2024
Updated data from a Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: focus on extrapulmonary neuroendocrine carcinomas (epNECs)
Author(s): Capdevila et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas
Author(s): Capdevila et al.
Tumor type(s): NEC
Compound/Target: DLL3/CD3 TcE
Tumor type(s): NEC
Compound/Target: DLL3/CD3 TcE
BRIGHTLINE-2
DAREON-5
